Plain-English translation of NCT06602479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a new medication called , which is given as a subcutaneous injection (under the skin). The trial is designed to see if this medication can help reduce the number of migraine headache days in adults with episodic migraines — particularly those who have already tried other preventive treatments without good results. About 488 people will participate, and roughly half will receive the new treatment while the other half receives a placebo (inactive injection) to compare results.
Many people with migraines don't find relief with currently available preventive medications, and doctors need new options. This medication works through a different mechanism than some existing treatments, and researchers want to understand whether it can safely and effectively reduce how many migraine days patients experience each month.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic multiple times over several months. During a 4-week baseline period before the study officially starts, you'll track your migraine headaches daily to establish a baseline. Once enrolled, you'll receive either the new medication or a placebo as a subcutaneous injection on a schedule determined by your assigned group. You'll continue tracking your migraines and attend follow-up visits so researchers can monitor your response to treatment and watch for any side effects. The study uses a 'double-blind' design, meaning neither you nor the researchers will know whether you're receiving the active medication or placebo until the study ends.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States